Severe haemophilia A patients have reduced numbers of peripheral memory B cells

Authors

  • M. B. IRIGOYEN,

    1. Instituto de Medicina Experimental-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • M. E. FELIPPO,

    1. Instituto de Medicina Experimental-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • L. PRIMIANI,

    1. Fundación Argentina de Hemofilia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • M. CANDELA,

    1. Instituto de Investigaciones Hematológicas-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • R. P. BIANCO,

    1. Fundación Argentina de Hemofilia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    2. Instituto de Investigaciones Hematológicas-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • M. M. DE BRACCO,

    1. Instituto de Medicina Experimental-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author
  • N. GALASSI

    1. Instituto de Medicina Experimental-Academia Nacional de Medicina de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
    Search for more papers by this author

Dra. Nora V. Galassi, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina de Buenos Aires, Pacheco de Melo 3081, C1425AUM-Ciudad Autónoma de Buenos Aires, Argentina.
Tel.: (+54.11) 4805 5695; fax: (+54.11) 4803 9475;
e-mail: ngalassi@hematologia.anm.edu.ar

Abstract

Summary.  The development of inhibitors is a complication of replacement treatment in Haemophilia. Loss of factor VIII-specific memory B cells in the spleen is associated with down regulation of antibodies in mice treated with high doses of FVIII, but changes in B cell memory have not been described in haemophilic patients. The aim of this study was to evaluate the phenotype of circulating lymphocytes in severe haemophilia A. Twenty patients with inhibitors (PI), 22 without inhibitors (P), nine patients during immune tolerance induction (ITI) treatment and 20 healthy donors (HD) were included. Peripheral blood lymphocytes were examined using flow cytometry. Anti-FVIII antibodies were measured using Bethesda and flow cytometry. Percentages of T subsets and B lymphocytes were similar in all groups. In contrast, memory B cells (CD27+) were decreased in PI and P compared with HD, but the level of significance was higher in PI (= 0.001) than P (= 0.01). PI with high level of anti-FVIII antibodies presented the lowest B memory values. CD70 expression was also lowest in PI. Non-switched CD27+ subpopulation (IgD+) was prevalent in PI, but did not show statistical significance. When ITI failed, the percentages of CD27+ B cells after 12 months of ITI were lowest. In a longitudinal study performed in four patients, an increased percentage of CD27+ and CD70+ B cells during ITI was found. This work suggests that different peripheral lymphocyte markers, such as CD27 and CD70 on B cells, may be helpful to evaluate anti-FVIII response and to monitor the success of ITI.

Ancillary